<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01503905</url>
  </required_header>
  <id_info>
    <org_study_id>BCSCO001</org_study_id>
    <nct_id>NCT01503905</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients</brief_title>
  <official_title>Comparison of the Effectiveness of Neoadjuvant Chemotherapy and the Outcomes Associated With Chemo-induced Amenorrhea Between Docetaxel Plus Epirubicin, and Docetaxel Plus Epirubicin Plus Cyclophosphamide as Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is a multicentre, randomized, open (unblended), prospective clinical trial
      which is sponsored by the researchers. The trial is designed to compare the effectiveness
      between docetaxel plus epirubicin, and docetaxel plus epirubicin plus cyclophosphamide as
      neoadjuvant chemotherapy for operable premenopausal breast cancer patients, and also to
      compare the outcomes associated with chemo-induced amenorrhea between the two neoadjuvant
      chemotherapies. The investigators will randomly assign 600 premenopausal female patients with
      operable breast cancer to receive four cycles of docetaxel and epirubicin (TE); or four
      cycles of docetaxel, epirubicin, and cyclophosphamide (TEC). After every two cycles of
      neoadjuvant chemotherapy, the investigators will estimate the effectiveness of therapy.
      Patients will undergo modified radical mastectomy or breast-conserving surgery after four
      cycles of neoadjuvant chemotherapy, and then receive postoperative chemotherapy (two cycles),
      radiation therapy, herceptin targeted therapy or hormone therapy according to the NCCN (2011)
      guideline. The follow-up will be ten years after surgeries. The primary aim is to examine
      whether the docetaxel and epirubicin (TE) will be as effective as the docetaxel, epirubicin,
      and cyclophosphamide (TEC) (pCR rate, cCR rate, PR rate, SD rate, progression-free survival
      (PFS) and overall survival (OS)). The secondary aim is to correlate chemo (TE/TEC)-induced
      amenorrhea with outcomes in premenopausal women.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival of patients.</measure>
    <time_frame>within 10 years after diagnosis</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival of the patients</measure>
    <time_frame>within 10 years after diagnosis</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The pathological remission rate of patients after neoadjuvant chemotherapy.</measure>
    <time_frame>within 80 days after diagnosis (after 4 cycles of neoadjuvant chemotherapy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The clinical remission rate of patients after neoadjuvant chemotherapy</measure>
    <time_frame>within 80 days after diagnosis (after 4 cycles of neoadjuvant chemotherapy)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Breast Cancer Nos Premenopausal</condition>
  <arm_group>
    <arm_group_label>Docetaxel plus epirubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>docetaxel plus epirubicin plus cyclophosphamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75mg/m2, iv injection, day1, every 21 days</description>
    <arm_group_label>Docetaxel plus epirubicin</arm_group_label>
    <arm_group_label>docetaxel plus epirubicin plus cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin</intervention_name>
    <description>80mg/ m2, iv injection, day1, every 21 days</description>
    <arm_group_label>Docetaxel plus epirubicin</arm_group_label>
    <arm_group_label>docetaxel plus epirubicin plus cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>500 mg/m2, iv injection, day1, every 21 days</description>
    <arm_group_label>docetaxel plus epirubicin plus cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Modified radical mastectomy or breast-conserving Surgery</intervention_name>
    <description>Two weeks after four cycles of neoadjuvant chemotherapy</description>
    <arm_group_label>Docetaxel plus epirubicin</arm_group_label>
    <arm_group_label>docetaxel plus epirubicin plus cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel (post-operative)</intervention_name>
    <description>Two weeks after surgery,75mg/m2, iv injection, day1, every 21 days, 4 cycles totally.</description>
    <arm_group_label>Docetaxel plus epirubicin</arm_group_label>
    <arm_group_label>docetaxel plus epirubicin plus cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin (post-operative)</intervention_name>
    <description>Two weeks after surgery, 80mg/m2,iv injection, day1, every 21 days, 4 cycles totally</description>
    <arm_group_label>Docetaxel plus epirubicin</arm_group_label>
    <arm_group_label>docetaxel plus epirubicin plus cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide (post-operative)</intervention_name>
    <description>Two weeks after surgery, 500mg/m2, iv injection, day1, every 21 days, 4 cycles totally.</description>
    <arm_group_label>docetaxel plus epirubicin plus cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>Two weeks after post-operative chemotherapy, perform radiation therapy based on 2011 NCCN guideline.</description>
    <arm_group_label>Docetaxel plus epirubicin</arm_group_label>
    <arm_group_label>docetaxel plus epirubicin plus cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin （post-operative)</intervention_name>
    <description>Perform herceptin therapy (one year) based on 2011 NCCN guideline if the pathological test of the operative tumor sample showed HER2 positive.</description>
    <arm_group_label>Docetaxel plus epirubicin</arm_group_label>
    <arm_group_label>docetaxel plus epirubicin plus cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen (post-operative)</intervention_name>
    <description>After radiation therapy, totally five years. Perform hormone therapy based on 2011 NCCN guideline if the tumor is ER/PR positive.</description>
    <arm_group_label>Docetaxel plus epirubicin</arm_group_label>
    <arm_group_label>docetaxel plus epirubicin plus cyclophosphamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patients signed the written informed consent.

          2. The patients present with operable breast cancers that were diagnosed by
             histopathology and have no distant metastasis.

          3. The patients have no history of anti-cancer therapies including chemotherapy,
             radiation therapy, hormone therapy and surgical therapy.

          4. The patients have normal cardiac functions by echocardiography.

          5. The patients' ECOG scores are ≤ 0-2.

          6. The age of patient is ≥ 18 years old; And the patients are premenopausal females.

          7. The patients are disposed to practice contraception during the whole trial.

          8. The results of patients' blood tests are as follows:

               -  Hb ≥ 90 g/L

               -  WBC ≥ 4.0×109/L

               -  Plt ≥ 100×109/L

               -  Neutrophils ≥ 1.5×109/L

               -  ALT and AST ≤ triple of normal upper limit.

               -  TBIL ≤ 1.5 times of normal upper limit.

               -  Creatinine ≤ 1.25 times of normal upper limit.

        Exclusion Criteria:

          1. The patients have other cancers at the same time or have the history of other cancers
             in recent five years, excluding the controlled skin basal cell carcinoma or skin
             squamous cell carcinoma or carcinoma in situ of cervix.

          2. The patients have active infections that were not suitable for chemotherapy.

          3. The patients have severe non-cancerous diseases.

          4. The patients are undergoing current administration of anti-cancer therapies, or are
             attending some other clinical trails.

          5. The patients whose breast cancers are HER2 positive and choose to undergo the
             neoadjuvant chemotherapy that includes herceptin regimen.

          6. The patients are pregnant or lactational, or they refuse to practice contraception
             during the whole trial.

          7. The patients are in some special conditions that they can't understand the written
             informed consent, such as they are demented or hawkish.

          8. The patients have allergic history of the chemotherapeutic agents.

          9. The patients have bilateral breast cancers.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fengxi Su, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-Sen Memerial Hospital of Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fengxi Su, M.D.</last_name>
    <phone>86-20-34071156</phone>
    <email>fengxisu@vip.163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The first People's Hospital of Foshan</name>
      <address>
        <city>Foshan</city>
        <state>Guangdong</state>
        <zip>528000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Yang</last_name>
      <phone>86-13902805191</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Women and Children Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antai Zhang</last_name>
      <phone>86-13925115929</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou Army General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chenfang Zhang</last_name>
      <phone>86-13889908978</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siyu Wang</last_name>
      <phone>86-18688464714</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhuanghong Wu</last_name>
      <phone>86-13602722502</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tumor Hospital of Guangzhou</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510095</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongsheng Li</last_name>
      <phone>86-13725111258</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pengxi Liu</last_name>
      <phone>86-13560333752</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fengxi Su</last_name>
      <email>fengxisu@vip.163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou Women and Children Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongmin Ma</last_name>
      <phone>86-13922723808</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first People's Hospital of Guangzhou</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhao</last_name>
      <email>gdzhaoli@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510260</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lehong Zhang</last_name>
      <phone>86-13719150959</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhujiang Hospital of Nanfang Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510282</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aiguo Wu</last_name>
      <email>wagtyz@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital of Nanfang Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changsheng Ye</last_name>
      <phone>86-13802954097</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Jinan University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ningxia Wang</last_name>
      <email>Twnx@Jnu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renbin Liu</last_name>
      <phone>86-13570073298</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongxian Zhou</last_name>
      <phone>86-13510363636</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first Affiliated Hospital of Shenzhen University</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518035</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianming Wang</last_name>
      <phone>86-13500056238</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2011</study_first_submitted>
  <study_first_submitted_qc>January 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2012</study_first_posted>
  <last_update_submitted>May 23, 2016</last_update_submitted>
  <last_update_submitted_qc>May 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Fengxi Su</investigator_full_name>
    <investigator_title>Director of Department of Breast Tumor Centre</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>amenorrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

